DE60008111D1 - Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn - Google Patents
Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirnInfo
- Publication number
- DE60008111D1 DE60008111D1 DE60008111T DE60008111T DE60008111D1 DE 60008111 D1 DE60008111 D1 DE 60008111D1 DE 60008111 T DE60008111 T DE 60008111T DE 60008111 T DE60008111 T DE 60008111T DE 60008111 D1 DE60008111 D1 DE 60008111D1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- derivatives
- naphtaquinone
- brain
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title abstract 4
- 229930195712 glutamate Natural products 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000614 1,2-naphthoquinonyl group Chemical class C1(C(C(=CC2=CC=CC=C12)*)=O)=O 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9909469 | 1999-07-21 | ||
| FR9909469A FR2796552A1 (fr) | 1999-07-21 | 1999-07-21 | Nouvelle utilisation de derives de la beta-naphtoquinone et de leurs sels pour la fabrication de medicaments exercant un effet inhibiteur sur la liberation de glutamate dans le cerveau |
| PCT/FR2000/002120 WO2001005404A1 (fr) | 1999-07-21 | 2000-07-21 | Utilisation de derives de la beta-naphtoquinone pour la fabrication de medicaments exerçant un effet inhibiteur sur la liberation de glutamate par le cerveau |
| CA2368850A CA2368850C (en) | 1999-07-21 | 2002-01-22 | Methods for the prevention and/or the treatment of glutamate cytotoxicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60008111D1 true DE60008111D1 (de) | 2004-03-11 |
| DE60008111T2 DE60008111T2 (de) | 2004-12-02 |
Family
ID=32178092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60008111T Expired - Lifetime DE60008111T2 (de) | 1999-07-21 | 2000-07-21 | Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7572774B2 (de) |
| EP (1) | EP1196176B1 (de) |
| AT (1) | ATE268599T1 (de) |
| CA (1) | CA2368850C (de) |
| DE (1) | DE60008111T2 (de) |
| DK (1) | DK1196176T5 (de) |
| ES (1) | ES2215716T3 (de) |
| FR (1) | FR2796552A1 (de) |
| PT (1) | PT1196176E (de) |
| WO (1) | WO2001005404A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027325A1 (en) * | 1993-05-07 | 1994-11-24 | Vlsi Technology, Inc. | Integrated circuit structure and method |
| EP1961738A1 (de) * | 2007-02-15 | 2008-08-27 | Faust Pharmaceuticals | Neue Verbindungen mit glutamatantagonistischen Eigenschaften und deren Verwendung |
| MX2018007272A (es) | 2015-12-16 | 2019-01-10 | Clevexel Pharma | Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60130515A (ja) * | 1983-12-15 | 1985-07-12 | Shiratori Seiyaku Kk | 血中２，３−ジホスホグリセリン酸上昇剤 |
| US5158976A (en) * | 1990-10-29 | 1992-10-27 | The Children's Medical Center Corporation | Controlling glutamine/glutamate related neuronal injury |
| GB9100028D0 (en) * | 1991-01-02 | 1991-02-20 | Ici Plc | Compounds |
| FR2707495B1 (fr) * | 1993-07-02 | 1995-09-01 | Roussel Uclaf | Nouvelle utilisation de dérivés de la béta-naphtoquinone ainsi que de leurs sels. |
| BE1011151A3 (fr) * | 1997-05-13 | 1999-05-04 | Jose Remacle | Utilisation d'une composition pharmaceutique dans le traitement et/ou la prevention de l'ischemie. |
| DE19751062A1 (de) * | 1997-11-18 | 1999-07-08 | Univ Ludwigs Albert | An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels |
-
1999
- 1999-07-21 FR FR9909469A patent/FR2796552A1/fr active Pending
-
2000
- 2000-07-21 WO PCT/FR2000/002120 patent/WO2001005404A1/fr not_active Ceased
- 2000-07-21 EP EP00958596A patent/EP1196176B1/de not_active Expired - Lifetime
- 2000-07-21 ES ES00958596T patent/ES2215716T3/es not_active Expired - Lifetime
- 2000-07-21 PT PT00958596T patent/PT1196176E/pt unknown
- 2000-07-21 DE DE60008111T patent/DE60008111T2/de not_active Expired - Lifetime
- 2000-07-21 AT AT00958596T patent/ATE268599T1/de not_active IP Right Cessation
- 2000-07-21 DK DK00958596T patent/DK1196176T5/da active
-
2002
- 2002-01-22 US US10/051,243 patent/US7572774B2/en not_active Expired - Fee Related
- 2002-01-22 CA CA2368850A patent/CA2368850C/en not_active Expired - Fee Related
-
2007
- 2007-05-11 US US11/798,285 patent/US20070225237A1/en not_active Abandoned
- 2007-05-11 US US11/798,284 patent/US20070225236A1/en not_active Abandoned
- 2007-05-11 US US11/798,283 patent/US20070225235A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1196176T3 (da) | 2004-06-14 |
| ES2215716T3 (es) | 2004-10-16 |
| US20070225237A1 (en) | 2007-09-27 |
| US20020115617A1 (en) | 2002-08-22 |
| DK1196176T5 (da) | 2004-07-12 |
| US20070225236A1 (en) | 2007-09-27 |
| WO2001005404A1 (fr) | 2001-01-25 |
| EP1196176B1 (de) | 2004-06-09 |
| CA2368850A1 (en) | 2003-07-22 |
| US20070225235A1 (en) | 2007-09-27 |
| CA2368850C (en) | 2010-12-07 |
| DE60008111T2 (de) | 2004-12-02 |
| PT1196176E (pt) | 2004-08-31 |
| FR2796552A1 (fr) | 2001-01-26 |
| EP1196176A1 (de) | 2002-04-17 |
| ATE268599T1 (de) | 2004-06-15 |
| US7572774B2 (en) | 2009-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE533484T1 (de) | Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| ATE212223T1 (de) | Verwendung von sertraline zur herstellung eines arzneimittels zur behandlung von obsessiv- kompulsiven erkrankungen | |
| IL111078A0 (en) | Inhibitors of beta-amyloid protein production | |
| ATE214287T1 (de) | Verwendung von relaxin zur herstellung eines arzneimittels für die behandlung kardiovaskulären krankeiten. | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| DE60142236D1 (de) | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung | |
| ATE299022T1 (de) | Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| ATE253932T1 (de) | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien | |
| ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| DE69923998D1 (de) | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE69713620D1 (de) | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia | |
| DE59508961D1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| DE69921662D1 (de) | Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose | |
| BG103687A (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system | |
| DE60008111D1 (de) | Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn | |
| ATE350027T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können | |
| ATE273006T1 (de) | Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas | |
| ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| IL143382A0 (en) | Human adult astrocytes, their preparation and uses thereof | |
| ATE189385T1 (de) | Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems | |
| DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |